Contineum Therapeutics Reports Third-Quarter 2026 Financial Results
Contineum Therapeutics, Inc. announced its financial results for the third quarter ended September 30, 2026.
Stocks · News reference
Contineum Therapeutics, Inc. 12-Month Price Target Adjusted to $21.43
Analysts have updated the 12-month price target for Contineum Therapeutics, Inc. to $21.43, reflecting a potential upside of approximately 121% based on the November 3, 2026, closing price.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — Contineum Therapeutics, Inc. (CTNM)
Filed: 2026-11-03 AccNo: 0001628280-26-069493 Size: 254 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Contineum Therapeutics to Present at the Stifel 2026 Healthcare Conference
Contineum Therapeutics, Inc. announced that its management team is scheduled to participate in a fireside chat at the Stifel 2026 Healthcare Conference on November 12, 2026.
Jones Trading Maintains Buy on Contineum Therapeutics, Raises Price Target to $30
This Chemours Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
Analysts downgraded CTNM, CC, ACI, BRKR and SAFE; targets fell for CTNM, CC and ACI, while BRKR received a new $60 target.
Baird Downgrades Contineum Therapeutics to Neutral, Lowers Price Target to $14
Baird analyst Joel Beatty downgrades Contineum Therapeutics (NASDAQ:CTNM) from Outperform to Neutral and lowers the price target from $19 to $14.